These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1385710)

  • 21. Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates.
    Donohue JH; Ramsey PS; Kerr LA; Segal DM; McKean DJ
    Cancer Res; 1990 Oct; 50(20):6508-14. PubMed ID: 2145062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
    Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
    Qian JH; Titus JA; Andrew SM; Mezzanzanica D; Garrido MA; Wunderlich JR; Segal DM
    J Immunol; 1991 May; 146(9):3250-6. PubMed ID: 1826709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted cellular immunotherapy with bifunctional antibodies.
    Nelson H
    Cancer Cells; 1991 May; 3(5):163-72. PubMed ID: 1832553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma.
    Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
    Cancer Res; 1995 Dec; 55(23 Suppl):5864s-5867s. PubMed ID: 7493361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Fucello AJ; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):361-8. PubMed ID: 1714644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
    Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
    Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
    Möller SA; Reisfeld RA
    Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.
    Xiang J; Koropatnick J; Qi Y; Luo X; Moyana T; Li K; Chen Y
    Immunology; 1993 Apr; 78(4):574-81. PubMed ID: 8495976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes.
    van Lier RA; Brouwer M; Rebel VI; van Noesel CJ; Aarden LA
    Immunology; 1989 Sep; 68(1):45-50. PubMed ID: 2530156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
    Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
    J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
    Molinolo A; Simpson JF; Thor A; Schlom J
    Cancer Res; 1990 Feb; 50(4):1291-8. PubMed ID: 2297774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytotoxicity of B72.3XOKT3 bispecific antibody recognizing human colon cancer.
    Shpitz B; Stern H; Sandhu JS; Reilley RM; Tropak MB; Jansz G; Xu J; Gallinger S
    J Surg Res; 1996 Feb; 61(1):134-8. PubMed ID: 8769955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies.
    Brissinck J; Demanet C; Moser M; Leo O; Thielemans K
    J Immunol; 1991 Dec; 147(11):4019-26. PubMed ID: 1940384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies to murine CD3 epsilon define distinct epitopes, one of which may interact with CD4 during T cell activation.
    Portoles P; Rojo J; Golby A; Bonneville M; Gromkowski S; Greenbaum L; Janeway CA; Murphy DB; Bottomly K
    J Immunol; 1989 Jun; 142(12):4169-75. PubMed ID: 2470817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
    van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
    Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.